Factors influencing oncologists’ prescribing hormonal therapy in women with breast cancer: a qualitative study in Córdoba, Argentina by Eraso, Yolanda
RESEARCH Open Access
Factors influencing oncologists’ prescribing
hormonal therapy in women with breast
cancer: a qualitative study in Córdoba,
Argentina
Yolanda Eraso
Abstract
Background: Hormonal therapy is an integral component for breast cancer treatment in women with oestrogen
receptor positive tumours in early-stage and advanced cases of the disease. Little is known about what factors
influence oncologists’ prescribing practices, especially non-biological factors, although this information may have
important implications for understanding inequalities in health care quality and outcomes. This paper presents
findings from research on factors influencing oncologists’ prescribing hormonal therapy for women with early and
advanced cases of breast cancer in the city of Córdoba, Argentina.
Methods: A qualitative study using in-depth, semi-structured interviews with 16 oncologists was conducted. A
stratified purposive sampling was used to recruit female and male participants and working at 3 health subsystems
(private, social security, public). Data was analysed using the Framework approach.
Results: According to the respondents, factors influencing prescribing practices of hormonal therapy are varied.
Women’s socio-economic status (poverty and wealth) and their level of health literacy can affect oncologists’
prescribing practices. Overall, in comparison to male, female oncologists reported more awareness of patients’
needs, more involvement in communicating drug side-effects, and in offering treatment options in private health
settings. The 3 health subsystems provided a differential access to drugs and lines of hormonal treatment, which
ranged from a limited availability in the public sector, to administrative restrictions imposed by the social security
system, and to a lesser extent, the private sector. This happened in the backdrop of national legislation covering
oncological treatments and drugs free of charge.
Conclusions: Addressing prescribing practices for hormonal therapy as a distinct type of breast cancer treatment
(chronic care) is fundamental in the understanding of breast cancer care and can shed light on inequalities in
treatments. Identifying the underlying care gaps in the prescription of hormonal therapy can help in the design of
tailored interventions.
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Background
Breast cancer (BC) is the most common cancer in women
worldwide. According to WHO, the burden of BC is in-
creasing in less developed countries where mortality rates
are higher due to late diagnosis and lack of treatment
facilities [1]. In Argentina, approximately 30–40% of BCs
are diagnosed at advanced stages of the disease (stages III
and IV) [2], and the survival rate of BC is 68.2%, below the
85% considered an international benchmark [3]. In
addition, inequalities in diagnosis are observed within the
different health subsystems whereby, according to RITA
hospital database, private centres detect most cases at clin-
ical stages 0, I and II, whilst public hospitals do so at stages
III and IV [4] (p.36).
Treatment developments in the last decades, in particu-
lar hormonal therapy (HT) for women with oestrogen
positive receptors, which accounts for ~ 70% of all BC
cases, has proven effective in reducing the risk of recur-
rence and in extending survival from the disease: in post-
menopausal women, 5 years of the anti-oestrogen drug
Tamoxifen (TAM) reduces the risk of recurrence by about
a half and mortality by about 30%, and Aromatase Inhibi-
tors (AI) reduce recurrence by about two-thirds and mor-
tality rate by around 40%, during 10 years after initiation
of treatment [5, 6].
In Argentina, BC is the cancer with the highest incidence
considering both sexes, followed by colorectum and pros-
tate cancer. According to GLOBOCAN (2018) [7] the
(ASR) incidence is 73, and (ASR) mortality is 18 cases ×
100.000. Although mortality rates for BC in Argentina have
followed a decreasing trend since 1997 [8] (p.31), it still oc-
cupies the second highest in South America after Uruguay.
In the province of Córdoba, the second most popu-
lated province with 3.308.876 inhabitants in the last cen-
sus (2010) [9], BC has an (ASR) incidence of 65.8 and
mortality of 21.4 × 100.000, whereas in the capital city
both rates are higher 77.1 and 23.7 respectively [10]. Ac-
cording to epidemiological regional data collected by the
National Institute of Cancer (2016), Córdoba is located
in the Centre Region - alongside Buenos Aires, Entre
Ríos, Santa Fe and the city of Buenos Aires (Federal
capital) - a region that has concentrated a higher BC
mortality rate (18.1) than the national average (17.4)
[11]. Socio-demographic data for the province of Cór-
doba indicates that the population group most affected
by BC (65+) is 23.4% of the population in 2016, and fe-
male life expectancy, according to the last census (2010),
is 79.2 years, in both cases showing higher values than
that for Argentina [12]. Also, an 8.7% of the population
of Córdoba has unmet basic needs (lower than national
level at 12,5%), and 1.3% of women are classified as
illiterate (lower than national average) [12]. However, a
recent ecology study on sociodemographic determinants
associated to the spatial distribution of BC in the
province, concluded that urbanisation was inversely as-
sociated to BC incidence, whereas deprivation (measured
as index of unmet basic needs per households) showed a
direct relationship [13]. Other indicators associated to
BC such as a good supply of health services in the cap-
ital (see Study setting below) that has traditionally served
the demand of nearby provinces, two University teaching
hospitals with specialisation in oncology, together with
an ageing female population and a higher than average
BC mortality rate make Córdoba a relevant case to
explore. Scholars have long emphasised the fragmented
nature of the Argentinian health system, which com-
prises three main subsystems (public, private, and social
security) with scarce synergy amongst them. Deficiencies
in cancer control have been observed not only in terms
of providers and resource management [14–16], but also
in terms of the lack of a National Cancer Programme
[17, 18], and inequalities in access to diagnosis and treat-
ments [19–21]. The health system in Córdoba is broadly
organised as follows: The majority of the working-age
population has the social security health insurance sys-
tem (Obra Social), each insurance plan being organised
according to the occupation of the beneficiary and are
administered by different workers unions. Within this
subsystem are also the provincial insurance plans for
civil servants, and a Comprehensive Medical Assistance
Program for retired people (Programa de Asistencia
Médica Integral, PAMI). A second group of high-income
earners have private health insurance (Medicina
pre-paga) offered by employers or contracted on an indi-
vidual basis. Finally, the public sector subsystem, for un-
insured people, is offered free of charge and financed
with resources from the provincial budget and national
funds for specific health programmes. According to data
from 2010, 69% of women were insured by the social se-
curity (49.73%), private health (17.44%), or state plan
(1.83%); whilst a 31% were uninsured [22].
Oncological treatments and cancer drugs approved
by national protocols are covered free of charge in
Argentina through the compulsory medical programme
(Programa Médico Obligatorio - PMO) [23], which ap-
plies to all health insurers including the public sector
that provides drugs (approved by a protocol) through
provincial health ministries. Despite these provisions to
guarantee free access to oncological drugs, a study
based on a survey of oncologists prescribing adjuvant
BC treatment in 2008, concluded that there were con-
siderable disparities between what oncologists thought
was an ideal treatment and what they actually could
prescribe to patients due to different restrictions. Re-
vealingly, only 40% were satisfied with the hormonal
treatment given [24]. This raises questions about acces-
sibility to treatment in a context of, in principle, univer-
sal drug coverage.
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Inequalities related to BC treatments outcomes have been
extensively documented in the US and European countries,
where modifiable social factors such as ethnicity, literacy,
doctor-patient’s communication, socio-economic status
(SES), drug accessibility, and health system provider
amongst others, have been variously identified as drivers
for different outcomes between affluent and disadvantaged
groups [25]. Understanding how these different factors
interact in complex ways is relevant to ensure an equitable
access to HT treatment, especially if we consider that the
benefits associated with HT imply a long-term process, as
recent guidelines recommend a 10-year course of therapy.
The significance of the latter has led authors, such as Beryl
and others [26], to differentiate patients’ decision-making
process into acute treatments (surgery, radiotherapy and
chemotherapy) and chronic care (HT), because of the irre-
versible/reversable nature of the decision, and the passive/
active role of treatment administration respectively. Much
of the quantitative and qualitative research on HT treat-
ments have focused on patients’ perceptions and experi-
ences in relation to adherence to treatments. Yet there is a
dearth of analysis focusing on what factors influence oncol-
ogists’ prescribing practices, the challenges they face and
how they overcome them. In addition, oncologists’ gender
is a variable that has rarely been explored in terms of inter-
actions with patients and decision-making patterns,
although it is known from studies on physicians more
broadly, that female doctors tend to deliver a more patient-
centred style of communication [27].
Hence, to help fill this gap in the literature, the aim of
this study was to explore the factors influencing oncolo-
gists’ prescribing practices of HT for women with early
and advanced BC in the city of Córdoba. The research
questions the study explored were: 1) What biological and
non-biological factors influence oncologists prescribing
HT?; 2) How does the oncologist’s gender affect HT
prescribing practices?; 3) How does the health system
provider affect oncologists' prescribing practices?
Methods
Study setting
The study was undertaken in the city of Córdoba, capital
of the homonymous province, where cancer treatment is
provided by different specialised services available through
the three health subsystems. These comprise the follow-
ing: 1) the institute of oncology (public sector) concen-
trates services on clinical oncology and radiotherapy for
the province, and provides oncological drugs to patients
there assisted and by referral from other provincial/uni-
versity hospitals. 2) oncology services provided by 4 pri-
vate hospitals and approximately 14 clinics with various
levels of complexity that have contracts with the different
social security and private health insurance plans. The dif-
ference between these providers is that the latter tend to
offer the most prestigious, state-of-the-art hospitals and
clinics, many of which are owned by the providers them-
selves. It is also worth emphasising that the patients
assisted in each of these subsystems often move across
services making the boundaries between them not so de-
marcated. On the one hand, the public institution grants
access to any person free of charge, so a patient in the pri-
vate/social insurance sector can seek a second opinion for
their treatment in the public sector or become a service
user when they have lost their jobs and their insurance
plans. On the other, a private clinic that predominantly re-
ceives users from the social security system can also offer
services to a handful of private health insurers. What is
clearer, is that uninsured patients only have access to the
public health system. For this study, the main public on-
cology institute, three private clinics (mostly social secur-
ity), and three private hospitals (mostly private health)
were purposively selected to encompass the three health
subsystems based on the list of oncology services available
at the provincial social security Web site [28] and through
communication with hospitals directors and heads of
oncology services (See Table 1).
Study design
A qualitative study design was developed to obtain insight
from oncologists who prescibe HT in the city of Córdoba.
The study employed individual semi-structured in-depth
interviews to explore biological and non-biological factors,
structural factors (health system) and personal character-
istics (gender) associated with HT decision-making and
prescribing practices as perceived by oncologists them-
selves. Adopting a thematic analysis approach (Framework
Table 1 Study Participants (n = 16)
Gender Participants (n)
Female 7
Male 9
Profession Participants (n)
Clinical Oncologist 13
Gynaecologic Oncologist 2
Radiation Oncologist 1
No. Years Oncology practice Participants (n)
0˗5 2
6˗10 3
11˗20 4
21˗30 4
More than 30 3
Health System Provider Participants (n)
Public health 6
Social Security (Obra social) 5
Private health insurance (Pre-paga) 5
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method) allowed for the identification of these pre-se-
lected themes as well as emergent themes generated from
the data. Moreover, a qualitative approach can offer depth
and detail on the experiences of oncologists’ prescribing
practices that could elicit the development of complemen-
tary quantitative studies.
Data collection
For data collection, a stratified purposeful sample was
used to obtain representatives of male/female oncologists
working at the different health subsystems. Because this
study wanted to explore the perspectives of oncologists in
prescribing HT, social aspects such as gender, and health
service provider – here used as a proxy to class – were
considered as relevant variables within the sample. Ac-
cording to Patton [29] (p. 240), ‘the purpose of a stratified
purposeful sample is to capture major variations rather
than to identify a common core, although the latter may
also emerge in the analysis. Each of the strata would con-
stitute a fairly homogeneous sample.’A total of 16 individ-
ual semi-structured in-depth interviews were conducted
with oncologists who regularly prescribed HT to women
in adjuvant and metastatic stages of BC disease.
Participants were identified and recruited through initial
contact with oncologists located at the 3 health subsystems
(1 director of hospital, 2 heads of services). All oncologists
interviewed were asked to further identify other potential
participants with personal contacts, to whom the researcher
contacted via telephone and email. The sample size was ini-
tially planned for around 20 participants and it followed
the concept of ‘information power’ [30] whereby the nar-
row aim of the study, the specificity of the participants in-
cluded and the theoretical background (health system and
gender) would offer sufficient focus for the interviews. 18
oncologists were approached and only 16 participated (1
interested but did not provide interview dates; 1
non-respondent). All interviews were conducted in Spanish
by the author, who is a native speaker, and is familiar with
health studies research on BC endocrine treatment and its
use amongst eligible patients. Interviews were digitally re-
corded at participants’ consulting rooms and hospital of-
fices during July 2016, and lasted between 37 and 101min.
An interview question guide was developed prior to the
recruitment process, which included a set of questions for
three different themes related to HT: prescribing, adher-
ence, and novel hormonal therapies. In this article, only
results on prescribing are presented, and the question
guide is available in Additional file 1.
Study sample
Participants for this study were 9 male and 7 female
doctors, with specialisation in clinical oncology, radi-
ation oncology, and gynaecological oncology. All with
experience in prescribing HT, and with a wide breath of
years in BC practice: For women, the median number of
practising years was 16.4 (range: 5–40); and for men
21.3 (range: 5–54). This reflects the late feminisation of
the oncology profession in the last 40 years.
Regarding the health service provider, participants
worked at different settings (clinics, hospitals, and insti-
tutes) corresponding to the 3 health subsystems. For this
study, the identification given to each of the 3 subsystems
has followed, in the case of private/social security, the main
type of population that the service assisted. Finally, it is also
common for doctors in Argentina to work at different insti-
tutions, and within this sample, a few oncologists worked
simultaneously in two different subsystems (one worked in
the private and public sector, and three did so at the social
security and the public sector). In this sense, the questions
were focused on their perceptions and working experience
of the specific setting where the interview took place.
After preliminary analysis of the data it was considered
that sufficient information power regarding relevant pat-
terns of prescribing practices was obtained before complet-
ing the 16 interviews. Characteristics of the sample are
provided in Table 1.
Data analysis.
All interviews were recorded with participants’ consent,
and transcribed verbatim by a research assistant with
experience in qualitative data management. The author
subsequently double checked the transcripts with the
recordings and translated it into English. Framework
analysis was used to analyse the data where a combined
approached was adopted, first, through a deductive process
based on the literature that informed the research questions
and secondly, through and inductive process based on par-
ticipants’ accounts [31]. Data were analysed following the
five methodological steps of the framework analysis: famil-
iarisation with the data, identification of a thematic frame-
work, indexing, charting, and mapping and interpretation
of themes [32]. Data was entered into a case chart for each
respondent were notes and extracts of relevant passages
were included for all identified themes (see Additional file 2
for an example of the case chart used). This allowed further
identification of patterns and associations during the map-
ping and interpretation process of the similarities and dif-
ferences in relation to gender and the health system
provider.
Data interpretation is reported here by using relevant
verbatim quotes to illustrate.
Quality assurance
In order to increase the internal validity of the data
collected, member checking was systematically used during
the interview and through the presentation of a summary
of the information collected to each participant at the end.
This allowed the investigator to paraphrase answers
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provided by each respondent, and to ensure understanding
and accuracy in the presentation of ideas.
To ensure reliability and confirmability of data collected
and analysed by a single researcher, the process of index-
ing (using textual codes) and charting was conducted in
two different stages. First, indexing and charting was de-
veloped by using the Spanish transcript. After translation
into English, a second round of indexing and charting
took place fourth months after the first one. The recoding
(crosschecking) of the two versions enhanced the process
of refining themes and subthemes, and ensured the elim-
ination of ambiguity of terms and lack of clarity, as well as
the researcher’s subjectivity and bias.
Results
Four core themes emerged from the analysis of the inter-
views: Biological and clinical factors; treatment guidelines;
patients’ socio-economic status; and the health-care pro-
vider (access to drugs). Several subthemes are clustered
under each core theme.
Biological and clinical factors
Tumour biology and age
The oncologists interviewed stated that the main indicator
for prescribing HT was the presence of oestrogen receptors
(ER+) alongside other markers such as progesterone values,
HER-2, and proliferation marker Ki-67. These corre-
sponded to the standard assessment of predictive factors,
with the exception of multi-gene profiling assay, which due
to costs, was not readily available. Other indicators consid-
ered were, disease stage: HT is prescribed for primary
(early) stage, and locally advanced BC where treatment
aims to reduce the risk of recurrence and is considered
‘curative’, and in advanced cases (metastasis) with
low tumour volume, where the role of HT is to extend
years of life. They also referred to prognostic factors such
as nodal status, especially for indication of chemotherapy in
young women before initiation of HT. Finally, the age of
the patient (pre or post menopause), and women < 35 year-
s-old who were considered as ‘higher risk’ patients. Oncolo-
gists were asked to describe in broad terms the indication
of HT for BC, and some described it this way:
With the immunohistochemistry report that expresses
the hormonal receptors, we have a predictive factor of
response. From there, we select which will be the
therapeutic tool of the hormonal therapy directed to
that disease: anti-oestrogens, aromatase inhibitors. If
pre-menopause, one therapeutic strategy will be pro-
vided for them, which is Tamoxifen; for post-
menopause it is possible to offer Tamoxifen and Aro-
matase Inhibitors which is not possible to give in pre-
menopausal women. […] Either because of risk issues
related to the disease or because one must weight
comorbidities, both will direct the selection of the
therapeutics, the hormone therapy more appropriated
for each case (09, male, social security).
Here [public hospital] we use the same as it is used in
the standard protocols whether national or
international. We use Tamoxifen as first line only as
long as receptors are positive in pre and
postmenopausal women. Then we will see in the
postmenopausal, depending on age, if we need to use
an Aromatase Inhibitor, such as Anastrazole or
Letrozole (02, female, public sector).
Whilst there were no relevant differences amongst re-
spondents in terms of the biological factors considered
for prescribing HT, most participants remarked on the
many biological considerations involved.
It is difficult to resume in few words because breast
cancer is one of the largest chapters in cancer
treatment (01, female, social security).
You are asking a question that is too general, which
demands a more specific answer. All depends on the
type of cancer, the receptors, the age of patients, […]
if you say a woman with 80 years-old with a conserv-
ing surgery, has receptors highly positive, it is a small
tumour, early stage, or doesn’t have risk factors, we
can go with conserving surgery, radiotherapy and hor-
mone therapy, yes, we can do [..] But if you have posi-
tive hormonal receptors with a HER-2+++, is totally
different (02, female, public sector).
Co-morbidities
Oncologist also expressed that patients’ clinical morbid-
ities at the start of the treatment alongside known drug
toxicities were important factors in the decision-making
process. For example, women with varicose veins and vas-
cular pathology were not prescribed TAM, and in patients
with osteoporosis, AIs were contraindicated. Also, because
AIs inhibit the conversion of androgens to oestrogens in
peripheral adipose tissue of postmenopausal women, in
the case of obese patients, AI-Letrozole was preferred to
AI-Anastrazole because of its treatment efficacy. Clinical
morbidity and drug toxicity, added to tumour biology, led
oncologists to develop a disease narrative of individual,
each case scenario. As these oncologists described it:
Each patient is unique. To one we make one scheme,
to another other (03, female, public sector).
The therapeutic guidelines start to personalise for
each case. From the general recommendation, one has
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to personalise, for each case, for each patient by name
and surname […] Women with the same disease can
have different therapies because each of them has its
own biological history (09, male, social security).
Treatment guidelines
In general terms, the protocols in use followed the clinical
practice guidelines from the American Society of Clinical
Oncology (ASCO), National Comprehensive Cancer Net-
work (NCCN), the European Society for Medical Oncology
(ESMO), and St Gallen International Breast Cancer Con-
sensus Conference. These guidelines have largely informed
the provincial protocol elaborated by the Córdoba Associ-
ation of Clinical Oncologists [33], whose recommendations
are harmonised with the largest provincial social security
provider (APPROS) that mainly covered workers in the
public health sector. Social security and private health pro-
viders also used international guidelines, however, they cov-
ered different drugs in their respective insurance plans.
Experience
Some oncologists, however, provided a more nuanced
account about the strict attachment to these guidelines, in
particular those with more years of practice, who
expressed some reserve based on experience, a preference
for meta-analysis, and familiarity with a drug. These were
identified in both male and female participants and in all
service providers:
I hate the guidelines ... here there is a great use of
guidelines, because doctors follow the guidelines and
they don’t read. […] I only follow meta-analysis and
all RCT with more than 10 years follow-up (04, fe-
male, social security).
One has acquired a certain experience that allows you
to continue practising with good parameters and with
acceptable results. Even though you are not using the
latest trend! […] Because we have seen many drugs,
things and projects that have disappeared because it
has been proven that they were not so useful as it was
initially thought (11, male, private health insurance).
There are ‘grey’ situations, where the experience and
opinion of each doctor sometimes counts more than
the guidelines, isn’t it? [..] In general the guidelines
contemplate all the options, if one sees the guidelines
they are not categoric because they are guidelines
precisely, are consensus of experts based in the
evidence (10, male, social security).
In another case, and although the ASCO (2016) guide-
lines and provincial protocol recommended the use of
TAM or AI for early stage ER+ postmenopausal women,
an oncologist expressed,
There is a tendency to use Aromatase Inhibitors in
postmenopausal patients over TAM. In my case no, I
prefer TAM and [Aromatase] Inhibitors I only use
them in those patients that could benefit due to the
risk of disease recurrence (08, male, social security).
Uncertainty
Some oncologists referred to the constant updating of guide-
lines, and the need to follow-up the new consensus achieved
by expert meetings. One oncologist described this as:
What I am using now [2016], maybe it will be
discussed in March 2017 (01, female, social security)
Another oncologist tried to reflect on the reason why
the guidelines for a drug like TAM has changed so much
over time:
When I graduated, we used to give Tamoxifen for life.
Later, it was for 5 years, then for 3 years, then it
returned to 5 years, and now is 10 years. There must
be a bias in all this… There is more money to
research certain things than others, which are the
ones that the industry is interested in, and they
allocate more money for that. I mean, not everything
is researched with the same allocation of funds… (05,
male, private health insurance).
Patients’ socio-economic status
Socio-economic position and life circumstances
In making a treatment decision, oncologists expressed
that patients’ socio-economic and socio-environmental
factors affected their treatment options, and believed
that their decisions were made in the patient’s interest.
This was mentioned in two scenarios, when deciding
amongst all treatments available, especially chemother-
apy; and when prescribing a particular drug (molecules)
corresponding to a hormonal line.
We need to bear in mind the [social] conditions and
the reality of patients. Sometimes we assist patients
of very poor social condition, that live in total
deprivation, overcrowded, so one needs to consider
these issues. How will you prescribe chemotherapy,
that can lead to neutropenia, leokopenia if you know
that the patient won’t have the support that she
needs? […] In those cases, we discuss within the team,
but we give hormonal therapy instead (14, male,
public sector).
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A poor woman, who lives isolated in a rural area, we
cannot use new molecules due to the toxicity
(neutropenia, diarrhoea). They need to be near a
hospital! (16, female, private health insurance).
Male oncologists in the public sector tended to see
socio-economic limitations as less problematic for the pre-
scription of HT in comparison to the weekly hospital visits,
transport costs, and health risks from chemotherapy:
The hormonal treatment is totally manageable. The
patient that uses TAM, the Ministry gives her 2/3
boxes, so for 3 months she doesn’t come, and you
realise in 3 months when she comes back to ask for
the renewal of the prescription (14, male, public
sector).
Female oncologists, however, considered HT prescrip-
tion as being sometimes problematic when low health
literacy was involved:
Many times it has happened to us that we give them
the medication and they return in 3 months, and they
say ‘I took it once Dr.’, this means that often they don’t
understand the treatment even when you write it down
for them, and even when they know how to read, they
don’t understand it (13, female, public sector).
Valuing the patient’s quality of life, women’s daily ac-
tivities and responsibilities, emerged as important factors
only for some female oncologists in the private sector.
For these doctors, assessing clinical factors was consid-
ered in tandem with social ones, thus both being
weighed in prescribing a particular hormonal line:
The patient decides. We consult all with the patient.
Sometimes they have a very active life, a work life, etc.
and we recommend a therapeutic line based on
toxicity. We mention side effects, such as fatigue
[aromatase inhibitors], and discuss options with them
(16, female, private health insurance).
Discussing treatment options
The discussion of treatment options with patients elic-
ited different perceptions. One respondent reflected with
a comparison with the shared decision-making model
that prevails in US and European contexts in relation to
patients’ engagement, information sharing and participa-
tion in treatment decisions.
In Argentina and Latin America there is a more
paternalistic attitude, that the population knows.
When one presents this [treatment options] to
patients and when we tell them, “if you don’t want to
do anything, it is your right”, they say “no, doctor, if
you are asking me, I will do it”. […] The patient
knows everything [treatments and side effects]
because one tells them, and they need to sign an
informed consent. We do have patients that reject
treatment, although not frequently (02, female, public
sector).
Male oncologists in particular, saw the issue of dis-
cussing treatment options with patients as a process
given by the whole therapeutic spectrum, as
information-sharing and patient’s decision regarding
acute treatment (surgery, radiotherapy and chemother-
apy). However, in the case of HT, male oncologists
tended to consider it as a benign, non-toxic treatment in
comparison to the acute ones, hence they did not con-
template the need to discuss with women the available
options. As one participant explained, the decision of
which hormonal line can be prescribed needed to be
taken by the specialist after assessing a woman’s clinical
condition (comorbidities).
In hormone therapy one evaluates the risk of the
patient. Today I saw a patient with phlebitis, this
makes her no eligible to treatment with Tam.
The election [aromatase inhibitor] was mine! I
proposed what I considered to be more effective for
her. But with chemotherapy no. Because we have
many more adverse effects, from the aggressiveness
for health, to what affects emotions, psychological,
aesthetics and psychospiritual wellbeing for the
patient. There, yes, it is possible to discuss, and the
patient participates actively in the election of
therapeutics or the rejection of the therapeutics. In
hormonal therapy no, because fortunately they are
very well tolerated (09, male, social security).
Health literacy
Most respondents perceived patients’ health literacy as
being stratified by social class. They largely concurred
about a clear distinction of patients’ behaviour across
the three health subsystems in terms of passive/active
interaction when treatment was communicated, and pa-
tients’ expectations during the encounter.
Female oncologists in the public sector acknowledged
that for patients with low health literacy, good communi-
cation and information, contention and encouragement
since the initiation of chemotherapy for advanced cases
(mostly observed in the public sector) was fundamental
for their ability to prescribe HT. A range of social support
offered by the provincial Ministries and a cancer NGO in-
cluding transport costs, education, and workshops,
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secured patients’ contention and prescription of HT as
chronic treatment.
Breast cancer is a chronic disease, so you need to give
tools to the person so she can be able to do
something with her life. So, if she hasn’t finished
school… or another activity is the prevention of
lymphedema, so we give women the tools for them to
do exercise for free, because they don’t have money
(02, female, public sector).
Male oncologists considered that the most deprived
and the most affluent patients could pose a ‘burden’ dur-
ing consultations for treatment prescription due to the
former not asking any questions at all, and the latter
asking too many questions. The following quotes exem-
plify how they experienced these interactions:
The lower the socio-economic position, the higher the
tendency to accept what the state offers them. The
higher the socio-economic level, the more demanding
are the individuals in relation to the health insurer, in-
stitutional services, doctors and the time they give to
them (10, male, social security).
If the doctor tells them what to do, they go and do it.
They generate a huge burden on us because they
don’t ask you anything, you see them totally
surrendered to what you tell them (14, male, public
sector).
Dr Google is an important colleague we have! There
is a lot of information out there but there is a need to
organise it. People read more, are more informed, and
Dr Google would be the first problem and Dr
Neighbour would be the second one. A neighbour
that tells her [patient] that she has an aunt, or a
cousin that has the same [disease] like her but she
was prescribed another thing... (05, male, private
health insurance)
We need to give them [patients] the information
why… the truth is that people ask for explanations.
On the other hand, today they are very informed by
the internet, so they keep abreast. […] Women ask
why this, why the other, which benefits and so on…
Here we are very nosy, you know that we are an
exigent society (07, male private health insurance).
The health-care provider (access to drugs)
Oncologists were asked about the main issue that af-
fected prescribing practices, and the one that the major-
ity identified was the different access to drugs. They
referred that each provider in the public, social security
and private sector covered different drugs, and therefore,
allowed them to prescribe different lines of hormonal
treatments. Some of the challenges that respondents
identified for each of the providers are presented below:
Prescribing outside the protocol
Oncologists working in the public sector spoke about
the limitations in accessing drugs that are outside the
protocol, which is the list of drugs that are provided by
the Ministry of Health of the province.
In the public sector is totally different from the [HT]
that is used in the private sector. [...] We have fewer
resources and they have imposed to us a protocol that
is very poor (14, male, public sector).
We usually do Tamoxifen in adjuvancy, that is what
we’ve got faster in terms of approval by the Ministry.
[…] We use more Tamoxifen in postmenopausal. That
will be perhaps the difference with other institutions.
Yes, due to cost and accessibility perhaps the
[Aromatase] Inhibitors are more used in private
settings. In general, we use Inhibitors as a second line,
or intolerance to Tamoxifen (12, female, public
sector).
At the same time, they referred that they did have access
to other drugs outside the protocol through a request to
the National Ministry of Social Development, but they
found the procedure very onerous. The comments were
that it was bureaucratic in terms of the paperwork in-
volved, time-consuming for the doctor, and tiring for the
patient. Some of them described this as follows:
We can have access to other type of medications, but
the procedure is a bit bothersome for the doctors and
also for the patient, because it is too much paperwork
involved, and the delays is around 60/90 days. But we
have access to other new medications like Palbociclib
or others like Fulvestrant, that we don’t have in our
protocol.
[…]
For a medication so common [Fulvestrant] that we
normally ask in the private sector or for patient in the
social security, to have to fill in a thousand forms [in
the public sector] and every 3 months to send all the
clinical records that demonstrate that [the patient] is
responding to treatment… We have overloaded with
patients, and many appointments and, on top of it,
the bureaucratic side … it tires you (14, male, public
sector).
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Dealing with social security and private insurance plans
For these providers there was, according to participants, a
larger range of drugs available, yet the accessibility to these
drugs varied according to the provider. Those who offered
newly available and expensive drugs also attempted to re-
strict access, through a highly bureaucratic process that in-
volved patients and oncologists. Most oncologists were able
to name specific drugs as accessible or not in the main so-
cial security and private insurance plans. They also men-
tioned certain, more expensive drugs (Exemestane,
Fulvestrant, Goserelin) that were covered in principle, but
doctors needed to justify why the drug has been recom-
mended. As many oncologists working in this subsector
concurred:
Treatment is according to patient and her social
insurance plan. […] In adjuvancy there is a strong
tendency to use Anastrozole in postmenopause
because a study gave 2.5% of benefit. Well, I’ll see…
because for the insurance plan is much more
expensive Anastrazole and the differences are very
little. If I see that they [social security] are not going
to give the medication, or they will delay it, or for the
patient is a cost, I am sure I will use Tamoxifen (04,
female, social security).
What we observe is that the insurer won’t reject up
front a drug prescribed because it doesn’t want to
enter into conflict with the patient […] and it starts,
in a subtle way, to put obstacles in the way of the
provision, avoiding to say up-front ‘I won’t cover it’,
but the patient enters in a complicated process with
paperwork and medical check-ups that wears the pa-
tient out in the request of the drug (09, male, social
security).
For a [drug] request, we have to deal with each social
security plan to see whether they will accept it or not,
some ask for more requirements, other less … It is
complex. It implies for doctors an onerous task,
because of paperwork, forms, reports, engagement
with auditors (10, male, social security).
However, the request of drugs in the private health
insurance was not perceived as a problem.
In general, it is standardised in the social security and
private health insurance to fill in a questionnaire for
the first time that one prescribes to a patient: to state
diagnosis, age of the patient, the objective why a drug
is requested, for how long. We make a kind of
protocol that we always do for the first time, but it is
not that they oblige us to put something special. It is
something standard […] an initial auditory. […] later
on, every time we use a new medication, they ask us
to fill in a form explaining why we change. But no
more than that (06, male, private health insurance).
We are here within the private sector and we have
greater accessibility, but we know that in the public
sector that is a bit more limited (07, male, private
health insurance).
Discussion
This qualitative study explored factors associated with
oncologists’ prescribing practices of HT for women with
oestrogen positive BC. To my knowledge, is the first
qualitative study on this topic conducted in Córdoba,
Argentina. HT is highly standardised in Western medi-
cine through consensus guidelines elaborated by profes-
sional associations in the US and Europe, based on
evidence-based clinical studies on populations. Whilst
adherence to these guidelines, in the sample studied,
seems to offer a consistent approach to treatment deci-
sions, patient-specific factors such as tumour biology,
clinical morbidity, drug toxicity, and tumour resistance
allowed oncologist to develop an individual-case ap-
proach. The role of experience in the older generation
also offered oncologists a way to exert choice and regain
clinical judgment in relation to the standardisation im-
posed by guidelines. In addition, two other factors re-
garding guidelines’ applicability explored by the
literature have been expressed by the respondents:
firstly, the local resource implications (drug availability),
which requires adaptability and consensus by the team
of specialists, as observed by a study on cytotoxic drugs
prescribing in the city of Rosario (Argentina) [34]. Sec-
ondly, the constant following of updates to guidelines to
keep peace with emerging data [35].
More importantly, a range of non-biological factors
appears to add complexity to the way the prescribing of
treatment is formulated. Factors associated with patients’
SES was an influencing component in decision-making
observed in this study, comprising three interrelated ele-
ments, socio-economic position, discussing treatment
options, and health literacy. Although patients’ SES has
not been specifically analysed in Argentina, a report ex-
ploring inequalities in access to drugs in the public sec-
tor pointed to the existence of ‘a cultural profile of the
public sector patient and the health professionals that
assist them, [as characterised by] a tendency to accept
the disease and its associated problems with resignation,
including the limitations of the care services’ [36] (n/p).
Overall, this study has shown that SES factors played a
role in prescribing HT treatment, and that there were
different approaches observed according to oncologists’
gender. Even when most respondents acknowledged the
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difficulties that women living in very deprived conditions
can pose to chemotherapy, male tended to consider HT as
a more acceptable treatment ‘for all social classes’ (14, male
public sector). This approach is, however, problematic, as it
associates HT with ‘taking a pill’, without considering
women’s self-management skills and understanding of the
treatment. Health literacy, i.e. having the skills, knowledge
and confidence to take decisions on medical instructions, is
largely associated with socio-economic circumstances,
whereby the most deprived groups are more likely to have
low health literacy [37]. However, as shown in this study,
highly educated women could also have limited health liter-
acy − which is understandable considering the complexity
associated with treatments regimes in HT − and therefore,
they were perceived by male oncologists as often demand-
ing and asking too many questions. There are only a hand-
ful of studies that have measured health literacy in specific
contexts in Argentina [38, 39], but there are none for can-
cer. This is an area that will require more research to
find out the implications it may have for health inequal-
ities: a study has demonstrated that BC oncologists
spend more time in consultations with highly educated
patients than with low-income, less educated ones [40],
whilst other studies, similarly to what have been identi-
fied here, have shown that most deprived patients have
greatest information needs and support in understand-
ing their disease and treatment [41, 42].
Previous research has noted that discussion of BC treat-
ment choices between oncologists and patients has been
associated with better health outcomes [43], and more
shared decision-making in adjuvant therapy was associated
with greater treatment satisfaction [44]. Whilst the process
of shared decision-making is not incorporated into Argen-
tina’s health policy, where a rather ‘paternalistic model’ pre-
vails with a right to informed consent [45], by considering
oncologists’ gender as a variable, this qualitative study has
shed light into how gendered power dynamics may affect
the process of prescribing in different ways: On the one
hand, female oncologists were more considered of the dif-
ferent side-effects that drugs can have in women’s quality
of life and so they were more prone to consider women’s
life circumstances and allow more educated women to
share their views and discuss treatment options. On the
other, the data collected suggest that prescribing practices
in male oncologists seem not to be influenced by these
considerations. Furthermore, male perceptions of both low
and upper-class women can inadvertently normalise issues
regarding women’s needs and understanding of treatment
options, foster a sense of adherence to treatment initiation
which may have implications for the amount of health
information provided. Moreover, this can also have further
implications for effective self-management, where oncolo-
gists and coordinated support from the health team is
needed for patients to make treatment decisions and
manage chronic conditions such as BC [26]. Hence, further
research is needed on health information interventions
such as patient decision aids, as evidenced by a Cochrane
review [46], designed to meet the information needs of the
different group of patients, according to their level of
health literacy.
The fragmented nature of the Argentinian health sys-
tem has often been identified as a cause of main health
inequalities, between and within provinces, including
cancer diagnosis and treatment [47] as well as access to
oncological drugs [36]. The perspective of oncologists
indicates that HT is strongly contingent on the health
system providers, which limit the line of treatments
(drugs) available from approximately 2 in the public sec-
tor to 7 in the private health insurance. Although oncol-
ogists tended to view these differences in the adjuvant
setting as non-fundamental in terms of a reported 2–3%
variation in drug effectiveness, in cases of metastatic BC
the differences between lines of treatments and health
outcomes can be more marked in overall survival as
shown in a recent review [48]. New drugs improving the
action of anti-oestrogens as well as different generations
of anti-oestrogens (SERD) and AIs open different se-
quence and combinations of treatments (Everolimus
with Exemestane or TAM; Palbociclib with Letrozole or
Fulvestrant). Precisely some of these targeted drugs are
the ones that appear as more challenging to access in
the social security and the public sector.
The recurrent mentioning of bureaucracy and paper-
work involved in accessing drugs that are not covered
within the Provincial/National protocol menu (public
sector), or that are covered (social security) but its ac-
cess is made very difficult by insurance plans can also
make the prescription of treatment dependent on both
determined oncologists and patients. Participants’ re-
sponses are in line with findings from Argentinian re-
ports whereby oncological patients in the public
sector referred to delays in access to medication due
to wrong prescriptions and complicated paperwork
from social services, as well as from national or pro-
vincial drug suppliers [18, 36]. For insured patients,
lawsuits have increasingly become an alternative way
of accessing oncological medicines [49]. In the private
health subsystem respondents saw the request of
drugs as less challenging. This could be due to a
more manageable workload for professionals, a better
coverage from the insurance plan or a simpler admin-
istrative procedure from the insurer. Finally, in
requesting drugs outside the protocol, oncologists
needed to consider, as one of them expressed, ‘The
possibility to sustain treatment in the future’ (07,
male private health insurance), that is, to balance the
risk of discontinuing treatment after an initial medi-
cation approval.
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Limitations
Some limitations of this study require careful consider-
ation. Although the participants within the sample repre-
sented the three health subsystems and oncologists’ gender,
it is possible that their views in relation to gender ap-
proaches to care, is not representative of all male/female
oncologists working in these different settings. Also, the
prescribing practices here described for the city of Córdoba
cannot be generalised to Argentina, even in the presence
of the same tri-partite health system. Gender notions, in
particular, are informed by societal factors, which may
largely differ amongst cities with different levels of commu-
nity values, medical education and training, and patients’
demands and expectations of care.
Conclusions
The findings of the study identified a number of themes
expressed by oncologists in their prescribing practices of
HT for BC women in Córdoba. Overall, the empirical data
collected suggests that HT is largely perceived by oncolo-
gists as a ‘different type’ of treatment, which is set ‘in com-
parison’ to the acute ones (surgery, chemotherapy and
radiation). Considering HTas a form of chronic care is fun-
damental to address the specificities involved in oncologists’
prescribing practices and in the understanding of HT use
among breast cancer patients. The intersections of
biological (tumour type, age and co-morbidities) and non-
biological factors (HT guidelines, patients’ SES, women’s
ability to understand HT, and access to drugs), alongside
the physician’s gender and the health system provider can
variously and simultaneously influence oncologists’ decis
ion-making. Given the different lines of treatments available
within HT (according to tumour type, age, co-morbidities,
and prognostic factors) effective communication of medica-
tion options can pose a challenge to oncologists and may
disadvantage women affected by the disease, by inhibiting
their comprehension of treatments options, benefits and
risks. The use of tailored interventions such as patient deci-
sion aids delivered to BC women pre or during consult-
ation, and designed according to the perceived health
literacy needs (e.g. for low-literacy groups, a web-based
interactive audio-visual intervention provided at the hos-
pital with the assistance of a nurse; for high-literacy groups,
a booklet or DVD using plain language), can facilitate
women’s informed decisions and make it easier for oncolo-
gists to discuss treatment options.
In this study, oncologists’ gender can be a contributory
factor on treatment decision-making. Female oncologists
in the private and public sector, tended to be more re-
sponsive to women’s needs, more prone to discuss treat-
ment options and drug toxicity. More qualitative research,
including patients, will contribute to advance knowledge
on oncologists’ gender as a specific factor, before policy
implications can be drawn.
Of significance, the fragmented health system can lead
to a differential access to drugs or lines of HT in the
metastatic BC setting between the public and private
sector; and also to a restricted access to drugs that are
covered through the insurance plans. Health system co-
ordination amongst the subsectors, a role assumed by
the Ministry of Health of the Province, should be im-
proved in terms of drugs accessibility if equity in access
is to be achieved. Initiatives should be taken to make the
provision of oncological drugs more streamlined and ac-
cessible to all service providers.
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